Shares of Achaogen, Inc. (NASDAQ:AKAO) have received an average rating of “Buy” from the thirteen research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $26.48.
A number of research firms have issued reports on AKAO. Mizuho reaffirmed a “buy” rating and issued a $28.00 price target on shares of Achaogen in a research report on Monday. Zacks Investment Research lowered Achaogen from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. BidaskClub raised Achaogen from a “hold” rating to a “buy” rating in a research report on Saturday, July 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $30.00 price target on shares of Achaogen in a research report on Friday, August 4th. Finally, Guggenheim began coverage on Achaogen in a research report on Tuesday, October 24th. They issued a “buy” rating and a $17.00 price target on the stock.
COPYRIGHT VIOLATION NOTICE: “Achaogen, Inc. (AKAO) Receives Average Rating of “Buy” from Analysts” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/11/03/achaogen-inc-akao-receives-average-rating-of-buy-from-analysts.html.
In other news, COO Blake Wise sold 3,576 shares of the stock in a transaction dated Tuesday, September 26th. The stock was sold at an average price of $15.99, for a total value of $57,180.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 8.36% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in AKAO. Legal & General Group Plc purchased a new position in Achaogen during the 2nd quarter worth approximately $168,000. Oppenheimer Asset Management Inc. purchased a new position in Achaogen during the 1st quarter worth approximately $199,000. Sigma Planning Corp grew its stake in Achaogen by 9.6% during the 2nd quarter. Sigma Planning Corp now owns 9,450 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 825 shares during the last quarter. Bank of Montreal Can grew its stake in Achaogen by 33.3% during the 2nd quarter. Bank of Montreal Can now owns 10,000 shares of the biopharmaceutical company’s stock worth $217,000 after buying an additional 2,500 shares during the last quarter. Finally, Ardsley Advisory Partners purchased a new position in Achaogen during the 2nd quarter worth approximately $217,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
Shares of Achaogen (AKAO) traded up $1.33 on Friday, reaching $14.04. 930,146 shares of the company were exchanged, compared to its average volume of 903,407. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.09.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.18). The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $2.69 million. Achaogen had a negative net margin of 281.88% and a negative return on equity of 86.24%. Achaogen’s revenue for the quarter was down 85.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.87) EPS. equities analysts forecast that Achaogen will post -3.01 earnings per share for the current year.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
What are top analysts saying about Achaogen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Achaogen Inc. and related companies.